12 Oversold Growth Stocks to Buy According to Analysts
On September 27, Wharton professor emeritus and WisdomTree senior economist Jeremy Siegel joined CNBC for an interview to discuss the latest PCE report and what the data reveal about the market.
Apellis Pharmaceuticals Inc. (APLS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 20,853 | $471,903 | -64% | 0.22% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.00 | 250,000 | $10,000,000.00 | 12,806,342 | 2021-11-18 | Filing | |
| $31.81 | 5,000 | $159,034.00 | 5,000 | 2020-05-08 | Filing | |
| $37.00 | 540,540 | $19,999,980.00 | 12,556,342 | 2020-01-13 | Filing | |
| $29.71 | 11,699 | $347,629.94 | 11,699 | 2019-08-29 | Filing | |
| $17.00 | 441,176 | $7,499,992.00 | 12,015,802 | 2019-03-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.03 | 10,000 | $280,300.00 | 110,936 | 2025-10-21 | Filing | |
| $25.22 | 5,000 | $126,100.00 | 113,730 | 2025-10-16 | Filing | |
| $23.72 | 31,092 | $737,536.44 | 3,837 | 2025-10-10 | Filing | |
| $22.58 | 31,092 | $702,057.36 | 33,979 | 2025-09-30 | Filing | |
| $22.95 | 31,092 | $713,561.40 | 68,908 | 2025-09-19 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,348,055 | $98,396,482 | 0.06% | |
| 2. | 620,790 | $14,048,478 | 0.05% | |
| 3. | 172,934 | $3,913,497 | 0% | |
| 4. | 3,122,000 | $3,196,891 | 0.02% | |
| 5. | 128,110 | $2,899,128 | 0% |
News See All
FDA Approval and Strategic Deals Drive Apellis Pharmaceuticals’ Stock Higher for the Week
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), headquartered in Massachusetts, is a global biopharmaceutical enterprise advancing treatments for diseases through complement system modulation.
11 Best Short-Term Stocks to Invest in
The latter half of the 2025 market is caught between conflicting signals.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2025 Earnings Call Transcript
Operator: Good day, and welcome to the Second Quarter 2025 Apellis Pharmaceuticals, Inc. Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target
In a market note on Wednesday, Scotiabank increased its price target for Apellis Pharmaceuticals, Inc.’s (NASDAQ:APLS) stock to $22 from $20 previously, and maintained a “sector perform” rating...
Apellis' EMPAVELI Approved by FDA for Rare Kidney Diseases
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.
10 Biotech Stocks to Buy According to Wall Street Analysts
On July 8, Jared Holz, Mizuho, joined 'Closing Bell Overtime' on CNBC to discuss if the biotech sector is ready for a breakout.
Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the most promising stocks according to Wall Street analysts.
16 Most Promising Stocks According to Wall Street Analysts
On July 3, Scott Wren, Wells Fargo senior global market strategist, and Adam Crisafulli, Vital Knowledge founder, joined 'Closing Bell Overtime' on CNBC to talk about the current market conditions.
Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.